Carregant...
Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy
The ataxia telangiectasia mutated serine/threonine kinase (ATM)/checkpoint kinase 2 (CHEK2, best known as CHK2) and the ATM and Rad3-related serine/threonine kinase (ATR)/CHEK1 (best known as CHK1) cascades are the 2 major signaling pathways driving the DNA damage response (DDR), a network of proces...
Guardat en:
| Publicat a: | Mol Cell Oncol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4905354/ https://ncbi.nlm.nih.gov/pubmed/27308506 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2015.1012976 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|